Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks
honglouwawa/iStock via Getty Images Shares of Regeneron (NASDAQ:REGN) have held up well despite the first quarter revenue and EPS miss. The stock is up 9% year-to-date, and it is outperforming the biotech benchmark ETFs despite the first quarter miss and the company receiving two complete response letters (‘CRLs’) from the FDA for odronextamab for the…